- Trials with a EudraCT protocol (291)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
291 result(s) found for: Pulmonary artery.
Displaying page 7 of 15.
EudraCT Number: 2014-004066-20 | Sponsor Protocol Number: AC-055-403 | Start Date*: 2015-05-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnet... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014377-40 | Sponsor Protocol Number: Bay 58-2667/14560 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002823-41 | Sponsor Protocol Number: AC-065B302 | Start Date*: 2019-06-03 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipa... | |||||||||||||
Medical condition: Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrent | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) BE (Completed) NL (Completed) HU (Completed) AT (Completed) BG (Completed) DK (Prematurely Ended) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021638-72 | Sponsor Protocol Number: HZC113782 | Start Date*: 2011-06-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmo... | |||||||||||||
Medical condition: Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Prematurely Ended) PL (Completed) GR (Completed) BG (Completed) ES (Completed) IT (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003482-68 | Sponsor Protocol Number: BAY 63-2521/12934 | Start Date*: 2008-11-26 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptom... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IE (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) FR (Completed) SE (Completed) GB (Completed) CZ (Completed) DK (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014378-16 | Sponsor Protocol Number: Bay 58-2667/14663 | Start Date*: 2010-01-14 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018173-31 | Sponsor Protocol Number: POISE-2 | Start Date*: 2011-02-25 | |||||||||||
Sponsor Name:Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |||||||||||||
Full Title: Ensayo clínico factorial de clonidina y aspirina en pacientes que van a ser sometidos a cirugía no cardiaca y que estén en riesgo moderado o alto de sufrir eventos cardíacos perioperatorios (Estudi... | |||||||||||||
Medical condition: Prevención de episodios cardiovasculares en pacientes de moderado a alto riesgo cardiovascular que son sometidos a una cirugía no cardiaca. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) AT (Completed) BE (Completed) DK (Completed) GB (Completed) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004220-23 | Sponsor Protocol Number: VIDEAT | Start Date*: 2008-09-04 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: EFFECT OF SUPPLEMENTATION WITH CHOLECALCIFEROL ON GLUCOSE AND LIPID METABOLISM, BLOOD PRESSURE, BONE MASS, QUALITY OF LIFE, CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH ISCHAEMIC HEART D... | |||||||||||||
Medical condition: ISCHAEMIC ARTERY DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018322-40 | Sponsor Protocol Number: AC-066A301 | Start Date*: 2010-05-20 | |||||||||||
Sponsor Name:ACTELION Pharmaceuticals Ltd | |||||||||||||
Full Title: A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004631-31 | Sponsor Protocol Number: REM-PH-416 | Start Date*: 2012-03-13 | |||||||||||||||||||||
Sponsor Name:United Therapeutics Corp. | |||||||||||||||||||||||
Full Title: A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pul... | |||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000097-26 | Sponsor Protocol Number: TDE-PH-310 | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) NL (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001598-10 | Sponsor Protocol Number: PB1046-PT-CL-0004 | Start Date*: 2020-01-24 | |||||||||||
Sponsor Name:PhaseBio Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adu... | |||||||||||||
Medical condition: Symptomatic Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006896-19 | Sponsor Protocol Number: CV185-047 | Start Date*: 2007-09-06 | |||||||||||||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Tota... | |||||||||||||||||||||||
Medical condition: Venous Thromboembolic Events | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) NL (Completed) AT (Completed) BE (Completed) FR (Completed) HU (Completed) SE (Completed) IT (Completed) CZ (Completed) DK (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002949-32 | Sponsor Protocol Number: SPHERE-HF | Start Date*: 2017-03-22 |
Sponsor Name:Fundació Clínic per la recerca Biomédica
[...]
1. Fundació Clínic per la recerca Biomédica
2. CNIC |
||
Full Title: β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial | ||
Medical condition: Pulmonary Hypertension secondary to heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2008-003303-31 | Sponsor Protocol Number: BAY59-7939/13238 | Start Date*: 2009-01-13 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer. | ||
Medical condition: Patients with acute, proximal DVT or acute PE who concomitantly use a strong CYP 3A4 inducer for the entire 3-month study duration. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-001067-36 | Sponsor Protocol Number: 18588 | Start Date*: 2016-11-21 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003076-14 | Sponsor Protocol Number: ANT-007 | Start Date*: 2022-05-10 |
Sponsor Name:Anthos Therapeutics | ||
Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in ... | ||
Medical condition: venous thromboembolism (VTE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002022-20 | Sponsor Protocol Number: NL61945.029.17 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mil... | |||||||||||||
Medical condition: We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002015-17 | Sponsor Protocol Number: 2016-002015-17 | Start Date*: 2017-03-10 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Low-flow Low-gradient Aortic Stenosis – Diagnostic Usefullness of Ivabradine | |||||||||||||
Medical condition: Aortic valve stenosis with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003688-37 | Sponsor Protocol Number: KKS-243 | Start Date*: 2018-07-06 | ||||||||||||||||
Sponsor Name:Philipps-Universität Marburg | ||||||||||||||||||
Full Title: Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controll... | ||||||||||||||||||
Medical condition: Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
